Nkarta Inc. (NASDAQ:NKTX) dropped some encouraging news on Wednesday: its experimental cell therapy NKX019 showed a clean safety profile in 40 patients across five different autoimmune diseases. The company presented the findings at the American College of Rheumatology's ACR Convergence 2026 conference in Orlando.
The headline number is zero. Zero deaths, zero severe immune toxicities, zero cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease across all dosing tiers. For a cell therapy, that's the kind of safety data that makes people sit up and pay attention.
What Makes NKX019 Different
Nkarta manufactures NKX019 from healthy donor-derived natural killer cells. The off-the-shelf, cryopreserved approach eliminates patient leukapheresis and individualized manufacturing delays, ensuring convenient delivery across clinical sites. In plain English: you don't have to extract a patient's cells, engineer them, and wait weeks for a custom batch. You pull a dose off the shelf.
The cumulative analysis, with a data cutoff of Sept. 18, 2026, evaluated patients battling active or progressive systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, and ANCA-associated vasculitis. These participants enrolled in the Ntrust Phase 1/2 clinical program after exhausting standard-of-care options.
And these were not mild cases. Thirty patients, or 75% of the cohort, had undergone four or more prior treatments. The study population recorded a median disease duration of 4.7 years, spanning from 0.3 to 30.7 years.
How the Dosing Worked
Participants received outpatient lymphodepletion using fludarabine and cyclophosphamide before receiving a three-dose cycle of NKX019. Nkarta evaluated three dose cohorts: five patients received 1 billion cells per dose, seven received 2 billion cells, and 28 received 4 billion cells.
Beyond the absence of severe immune toxicities, physicians reported no fludarabine-related leukoencephalopathy, and no patients discontinued treatment due to adverse events. That last point matters because in sick patient populations, tolerability often determines whether a therapy gets a real shot.
Manageable Adverse Events
Treatment-emergent adverse events occurred in 34 individuals, with 14 patients developing grade 3 or higher complications. Clinicians predominantly attributed these high-grade events to preconditioning chemotherapy. Most hematologic abnormalities resolved within one to two months, though five patients experienced grade 3 or higher cytopenias persisting past 28 days. Adverse event frequency remained stable across all dose levels.
NKTX Price Action: Nkarta shares were up 3.70% at $1.40 at the time of publication on Wednesday, according to market data.
